Pharmacokinetics of lubeluzole (Prosynap) after single intravenous doses in healthy subjects.
Int J Clin Pharmacol Ther
; 36(9): 490-3, 1998 Sep.
Article
em En
| MEDLINE
| ID: mdl-9760010
ABSTRACT
The single-dose pharmacokinetics of lubeluzole were investigated in 2 single-blind, placebo-controlled, dose-escalation studies in healthy male subjects. In the first study, 6 subjects received an intravenous infusion of 2.5, 5, and 10 mg lubeluzole. In the second study, a 15 mg dose of lubeluzole was administered to 6 subjects, of whom 5 also received 20 mg and 2 also 25 mg lubeluzole. Following the infusion, plasma lubeluzole concentrations decayed biphasically, with a mean distribution half-life (t1/2alpha) of 30 to 65 minutes and a mean terminal half-life (t1/2beta) of 15 to 24 hours. The results of the 2 studies indicate that lubeluzole exhibits linear kinetics over the dose range tested in healthy male subjects.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Piperidinas
/
Tiazóis
/
Fármacos Neuroprotetores
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Int J Clin Pharmacol Ther
Assunto da revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
1998
Tipo de documento:
Article
País de afiliação:
Bélgica